Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 6/20 | 1.00 |
| ▸ | RORC | P51449 | 5/20 | 1.00 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.85 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.85 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.84 |
| ▸ | CRYAB | P02511 | 1/20 | 0.80 |
| ▸ | HMGCR | P04035 | 1/20 | 0.80 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.80 |
| ▸ | ITGAV | P06756 | 1/20 | 0.80 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.80 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.80 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.80 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.77 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.75 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL21707472 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21539517 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL22095727 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21447271 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23579652 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21340667 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23365796 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21650234 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23761109 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21445079 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 787 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139254-A1 | INTERFERING RNA FOR INHIBITING TOP1 GENE EXPRESSION AND USE THEREOF | JENKEM TECH CO LTD BEIJING (CN) | 2026-05-21 | — | — | US | claimed |
| EP-4721759-A1 | LIPID NANOPARTICLE FOR DELIVERING NUCLEIC ACID DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Cansino (Shanghai) Biological Research Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-12582610-B2 | Lipid-polymer compositions and methods of use | Max Biology Co. Ltd. (KH) | 2026-03-24 | — | — | US | claimed |
| US-12576039-B2 | Lipid-polymer compositions and methods of use | Max Biology Co. Ltd. (KH) | 2026-03-17 | — | — | US | claimed |
| EP-4707289-A1 | STEROID-CATIONIC LIPID COMPOUND AND USE THEREOF | Cansino (Shanghai) Biological Research Co., Ltd. (CN) | 2026-03-11 | — | — | EP | claimed |
| EP-4342929-B1 | POLYETHYLENE GLYCOL LIPID AND USE THEREOF | JENKEM TECH CO LTD TIANJIN (CN) | 2026-02-04 | — | — | EP | claimed |
| EP-4365168-B1 | POLYOL-MODIFIED LIPID COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | JENKEM TECH CO LTD TIANJIN (CN) | 2025-10-15 | — | — | EP | claimed |
| US-20250313844-A1 | INTERFERING RNA FOR INHIBITING PCSK9 GENE EXPRESSION AND USE THEREOF | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2025-10-09 | — | — | US | claimed |
| EP-4628496-A1 | STEROID-CATIONIC LIPID COMPOUND AND USE THEREOF | Jenkem Technology Co., Ltd. (Liaoning) (CN) | 2025-10-08 | — | — | EP | claimed |
| EP-4628497-A1 | STEROID-CATIONIC LIPID COMPOUND AND USE THEREOF | Jenkem Technology Co., Ltd. (Liaoning) (CN) | 2025-10-08 | — | — | EP | claimed |
| WO-1999061481-A1 | AMPHIPHILIC POLYSACCHARIDE DERIVATIVES | MEDIPLEX CORPORATION, KOREA (KR) | 1999-12-02 | — | — | WO | claimed |
| US-5885565-A | APPLYING TO THE EPITHELIUM OF THE HOST, AN EFFECTIVE AMOUNT OF ONE OR MORE PENETRATION ENHANCING EPITHELIAL STEROLS AND THERAPEUTICAL OR PROPHYLACTIC AGENT | CELLEGY PHARMACEUTICALS INC. (US) | 1999-03-23 | — | — | US | claimed |
| US-5876993-A | ENZYME ISOLATED FROM MYCOBACTERIUM WHICH CONVERTS 5-CHOLESTEN-3-ONE TO EPICHOLESTEROL WHICH IS ABSORBED POORLY IN INTESTINES; FOR CHOLESTEROL-REDUCED FOODS AND FEEDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-03-02 | — | — | US | claimed |
| US-5503988-A | Process for producing a cholesterol-reduced substance | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-04-02 | — | — | US | claimed |
| EP-0693932-A1 | METHODS AND COMPOSITIONS FOR INDUCING PHASE SEPARATION OF EPITHELIAL LIPID BILAYERS | CELLEGY PHARMACEUTICALS, INC. (US) | 1996-01-31 | — | — | EP | claimed |
| EP-0664129-A2 | Epicholesterol for treating dyslipidemia | PHARMACIA S.p.A. (IT) | 1995-07-26 | — | — | EP | claimed |
| WO-1994021271-A1 | METHODS AND COMPOSITIONS FOR INDUCING PHASE SEPARATION OF EPITHELIAL LIPID BILAYERS | CELLEGY PHARMACEUTICALS, INC. (US) | 1994-09-29 | — | — | WO | claimed |
| EP-0606485-A1 | PROCESS FOR PRODUCING SUBSTANCE LOWERING CHOLESTEROL LEVEL | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-07-20 | — | — | EP | claimed |
| CN-1073179-A | Novel glycoside compounds and preparation thereof and purposes | HARRIER INC (US) | 1993-06-16 | — | — | CN | claimed |
| WO-1993004672-A1 | METHOD FOR ENHANCING THE IMMUNE SYSTEM IN A HOST EMPLOYING LIPOSOME-ENCAPSULATED POLYPEPTIDES | PITMAN-MOORE, INC. (US) | 1993-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576039-B2 | Lipid-polymer compositions and methods of use | HDLBP, VEGFA, CNR2 | OSBP 947/4885RORC 250/4885OSBP2 1587/4885 |
| US-20260139254-A1 | INTERFERING RNA FOR INHIBITING TOP1 GENE EXPRESSION AND USE THEREOF | TOP1, TOP2A, TOP2B | OSBP 858/4885RORC 4035/4885OSBP2 1213/4885 |
| US-12582610-B2 | Lipid-polymer compositions and methods of use | PGF, HDLBP, VEGFA | OSBP 519/4885RORC 515/4885OSBP2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.